IRMarketingPRStrategy
Reverse Merger – Investor Credibility & Visibility
National, Clinical, Pre-clinical, Public
A reverse merger into a public shell with a complex, warrant-heavy capital structure created challenges for a clinical-stage company developing transformative gene therapies and biologics. LHS aimed to support Ocugen’s efforts to leverage its transformative technology with investors – including VCs and institutional investors. The goal was maintaining interest and building commitment of existing retail investor shareholder base.
LHS Solution
- Implemented a comprehensive suite of investor relations services – from strategic counsel to tactical execution and administrative support
- Communicated extensively to set expectations with existing retail shareholder base through consistent messaging around milestones, operational goals and financial guidance
- Employed LHS’ extensive capital markets contacts to introduce management to key investors and solicit unbiased investor feedback on company story
- Developed new investor presentation using LHS Fifteen Slide® Presentation methodology
Results
- Stabilized stock price volatility, short interest swings and trading volume spikes
- Developed new communications vehicles to successfully engage with both retail and institutional investors
- Expanded presence into high profile investor and medical conferences
- Prominent initial sell-side analyst coverage – Chardan Capital, HC Wainwright
- Secured top-tier media coverage and developed thought leadership opportunities for senior management
